New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC® Therapy

Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device Therapy

MANSFIELD, Mass., March 15, 2023 /PRNewswire/ -- BioVentrix^®, Inc., a privately held medical device company developing less invasive therapies to directly treat the dilated left ventricle leading to progressive heart failure, today announced the publication of a peer-reviewed paper in the Journal of Clinical Medicine, titled, Inward Displacement, A Novel Approach to Measuring Left Ventricular (LV) Function in Patients with HFrEF after Undergoing BioVentrix Therapy.

The study demonstrated that the Inward Displacement method provides an accurate measurement of improvement in regional LV function in patients who had been treated with the BioVentrix Revivent TC® device. To date, there have been limited techniques employing cardiac CT and/or MRI to accurately assess the regional function in ischemic, dilated left ventricles in the HFrEF population. The Inward Displacement measurement technique was developed to overcome these limitations. When compared to speckle tracking echocardiography, it has been shown to accurately measure the improvement in LV function.

"This novel methodology gives us the ability to not only more accurately quantify LV function globally, but also to provide information on regional LV structure and function," said Rishi Puri, MD, PhD, Coronary & Structural Interventional Cardiologist, Cleveland Clinic, Cleveland, OH.  "Our data demonstrates that the Revivent TC procedure not only globally reduces LV volume, but also improves the regional function of the non-infarcted myocardium, thereby reversing the adverse remodeling which occurs in these patients."

Inward Displacement was analyzed across two groups of HFrEF patients who underwent Left Ventricular Restoration with Revivent TC. 36 patients were operated on after maintaining optimized guideline-directed medical therapy for at least 90 days and had pre- and post-operative CT- or CMR-scans with sufficient quality for analysis. Patients studied using this method demonstrated an improvement in regional wall motion in the basal and mid LV segments once the non-functioning scarred LV segments were plicated. These findings point to an improvement in function of the non-scarred areas.

"Imaging the heart with cardiac CT and MRI has gained importance in the care of patients with heart failure, but until now there have been limitations in assessing and quantifying function in the different walls of the heart," said Ori Ben-Yehuda, MD, FACC, Chief Medical Officer of BioVentrix. "The Inward Displacement method was developed to accurately quantify regional heart function. It has now been demonstrated to accurately measure the improvement in LV function following treatment with Revivent TC therapy and further validates the efficacy of our therapy."

About the Revivent TC® System

The BioVentrix Revivent TC System is designed to support a minimally invasive procedure to treat a dilated left ventricle of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and extensive left ventricular scar, who have a suboptimal response to guideline-directed medical therapy.  The procedure, referred to as Less Invasive Ventricular Enhancement (LIVE^®) therapy, utilizes myocardial micro-anchor implants to reconstruct the dilated left ventricle to produce a more efficient chamber. 

The company announced that it had received approval from the Food and Drug Administration (FDA) for an Expanded Access Program following the successful completion of enrollment in the ALIVE (American Less Invasive Ventricular Enhancement) Trial, a prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System. Enrollment in the ALIVE Trial was completed in April 2022.

About BioVentrix

BioVentrix, Inc. is a privately held medical device company focused on the development of less invasive therapies to treat the failing left ventricle (LV), the most common cause of heart failure. BioVentrix technologies aim to improve cardiac function by directly addressing LV dilation. The Company markets the Revivent TC System in Europe and is preparing to submit the Premarket Approval (PMA) application to the FDA for the system later this year.

The BioVentrix, LIVE and Revivent TC trademarks are federally registered trademarks owned by BioVentrix. Any unauthorized use is expressly prohibited.

Investigational Device. Limited to Investigational Use Only in The United States.

SOURCE BioVentrix, Inc.